Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 9;9(3):123397.
doi: 10.51894/001c.123397. eCollection 2024.

Current Pharmacologic Options and Emerging Therapeutic Approaches for the Management of Ulcerative Colitis: A Narrative Review

Sneha Annie Sebastian  1 , Oroshay Kaiwan  2 , Edzel L Co  3 , Meghana Mehendale  4 , Babu P Mohan  5
Affiliations
Review

Current Pharmacologic Options and Emerging Therapeutic Approaches for the Management of Ulcerative Colitis: A Narrative Review

Sneha Annie Sebastian et al. Spartan Med Res J. .

Abstract

Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disorder (IBD) with periods of relapse and remission. Current advancements in clinical research have led to the development of more refined and effective medical therapy for UC.

Summary of the evidence: Traditional therapeutic agents such as 5-aminosalicylates (5-ASAs), sulfasalazine (SASP), corticosteroids, and immunomodulatory drugs have remained the gold standard for decades. However, their novel formulations and dosage regimens have changed their sequences in the medical management of UC. Several other novel drugs are in the final phases of clinical development or have recently received regulatory approval designed to target specific mechanisms involved in the inflammatory cascade for UC.

Conclusions: This narrative review sought to provide a comprehensive knowledge of the potential benefits of standard and emerging therapies, including novel formulations, new chemical entities, and novel therapeutic approaches in managing UC. Keywords: Ulcerative colitis, 5- Aminosalicylic acid, sulfasalazine, corticosteroids, biologics, immunomodulators, novel formulations.

Keywords: 5- Aminosalicylic acid; Ulcerative colitis; biologics; corticosteroids; immunomodulators; novel formulations; sulfasalazine.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1.
Figure 1.. Representation of treatment goals of ulcerative colitis
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. 5-ASA to sulfasalazine drug switch program in patients with ulcerative colitis. Goldsmith J. R., Waljee George T., Brown A., Choe H. M., Noureldin M.., et al. 2018The American journal of managed care. 24(8 Spec No.):SP303–SP308. - PubMed
    1. Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab. Barrie A., Plevy S. 2006Gastroenterology clinics of North America. 35(4):883–893. doi: 10.1016/j.gtc.2006.09.001. https://doi.org/10.1016/j.gtc.2006.09.001 - DOI - DOI - PubMed
    1. Current Directions in IBD therapy: what goals are feasible with biological modifiers? Sandborn W. J. 2008Gastroenterology. 135(5):1442–1447. doi: 10.1053/j.gastro.2008.09.053. https://doi.org/10.1053/j.gastro.2008.09.053 - DOI - DOI - PubMed
    1. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Sutherland L., MacDonald J. K. 2003The Cochrane database of systematic reviews. (3):CD000543. doi: 10.1002/14651858.CD000543. https://doi.org/10.1002/14651858.CD000543 - DOI - DOI - PubMed
    1. Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents. Yasutomi E., Hiraoka Y., Yamamoto S., Oka S., Hirai M., Yamasaki Y.., et al. 2019Journal of clinical medicine. 8(12):2109. doi: 10.3390/jcm8122109. https://doi.org/10.3390/jcm8122109 - DOI - DOI - PMC - PubMed

Grants and funding

None

LinkOut - more resources